Login to MyKarger

New to MyKarger? Click here to sign up.



Login with Facebook

Forgot your password?

Authors, Editors, Reviewers

For Manuscript Submission, Check or Review Login please go to Submission Websites List.

Submission Websites List

Institutional Login
(Shibboleth or Open Athens)

For the academic login, please select your country in the dropdown list. You will be redirected to verify your credentials.

Clinical Investigations

Cytokine mRNA Expression in Isocyanate-Induced Hypersensitivity Pneumonitis

Sumi Y. · Kyi M. · Miyazaki Y. · Ohtani Y. · Miyake S. · Yoshizawa Y.

Author affiliations

The Pulmonary Medicine, Tokyo Medical and Dental University, Tokyo, Japan

Related Articles for ""

Respiration 2003;70:284–291

Do you have an account?

Login Information





Contact Information












By signing up for MyKarger you will automatically participate in our year-End raffle.
If you Then Do Not wish To participate, please uncheck the following box.

Yes, I wish To participate In the year-End raffle And Get the chance To win some Of our most interesting books, And other attractive prizes.


I have read the Karger Terms and Conditions and agree.



Login Information





Contact Information












By signing up for MyKarger you will automatically participate in our year-End raffle.
If you Then Do Not wish To participate, please uncheck the following box.

Yes, I wish To participate In the year-End raffle And Get the chance To win some Of our most interesting books, And other attractive prizes.


I have read the Karger Terms and Conditions and agree.



To view the fulltext, please log in

To view the pdf, please log in

Buy

  • FullText & PDF
  • Unlimited re-access via MyKarger
  • Unrestricted printing, no saving restrictions for personal use
read more

CHF 38.00 *
EUR 35.00 *
USD 39.00 *

Select

KAB

Buy a Karger Article Bundle (KAB) and profit from a discount!

If you would like to redeem your KAB credit, please log in.


Save over 20% compared to the individual article price.
Learn more

Rent/Cloud

  • Rent for 48h to view
  • Buy Cloud Access for unlimited viewing via different devices
  • Synchronizing in the ReadCube Cloud
  • Printing and saving restrictions apply

Rental: USD 8.50
Cloud: USD 20.00


Select

Subscribe

  • Access to all articles of the subscribed year(s) guaranteed for 5 years
  • Unlimited re-access via Subscriber Login or MyKarger
  • Unrestricted printing, no saving restrictions for personal use
read more

Subcription rates


Select

* The final prices may differ from the prices shown due to specifics of VAT rules.

Article / Publication Details

First-Page Preview
Abstract of Clinical Investigations

Received: February 10, 2003
Accepted: November 26, 2012
Published online: August 18, 2003
Issue release date: May – June

Number of Print Pages: 8
Number of Figures: 4
Number of Tables: 2

ISSN: 0025-7931 (Print)
eISSN: 1423-0356 (Online)

For additional information: https://www.karger.com/RES

Abstract

Background: Diisocyanate is widely used as a polymerizing agent for manufacturing many products. However, repeated inhalation exposure to diisocyanates in the workplace can cause bronchial asthma, hypersensitivity pneumonitis (HP), and neoplasia. Objectives: In the current study, immunological tests were conducted to explore the mechanisms involved in the pathogenesis of diisocyanate-induced HP. Methods: Evaluations included 4 patients with diisocyanate-induced HP, 4 volunteers with current occupational exposure to diisocyanates and 4 normal volunteers without a history of exposure to diisocyanates. IgG and IgA antibody levels to diisocyanates were determined by ELISA in sera and BAL fluids. Peripheral blood mononuclear cells (PBMCs) were cultured in the presence or in the absence of 10 µg/ml MDI-HSA (4, 4′ diphenylmethane diisocyanate)-HSA (human serum albumin). 3H-thymidine uptake, mRNA expression by RT-PCR (beta-actin, IL-1beta, IL-2R, IL-4, IL-5, IL-6, IL-10, IFN-gamma, TNF-alpha, TGF-beta) were estimated. Results: Patients with diisocyanate-induced HP had detectable IgG and IgA antibodies to diisocyanates. In addition, PBMCs from HP patients proliferated in the presence of diisocyanates and showed enhanced expression of mRNA of proinflammatory cytokines. In contrast, normal volunteers with current occupational exposure showed elevated levels of mRNA expression of IL-10 and IL-2R, suggesting the presence of sensitized cells and protection from pathology as a result of enhanced IL-10 production. Conclusions: Patients with diisocyanate-induced HP are likely to override the protective effects of IL-10 as they express lower levels of this cytokine.

© 2003 S. Karger AG, Basel


References

  1. Vandenplas O, Malo JL, Saetta M, Mapp CE, Fabbri LM: Occupational asthma and extrinsic alveolitis due to isocyanates: Current status and perspectives. Br J Ind Med 1993;50:213–228.
  2. Vandenplas O, Malo JL, Dugas M, Cartier A, Desjardins A, Levesque J, Shaughnessy MA, Grammer LC: Hypersensitivity pneumonitis-like reaction among workers exposed to diphenylmethane [correction to diphenylmethane] diisocyanate (MDI). Am Rev Res Dis 1993;147:338–346.
  3. Raulf-Heimsoth M, Baur X: Pathomechanisms and pathophysiology of isocyanate-induced diseases – Summary of present knowledge. Am J Ind Med 1998;34:137–143.
  4. Hunninghake GW, Gadek JE, Kawanami O, Ferrans VJ, Crystal RG: Inflammatory and immune processes in the human lung in health and disease: Evaluation by bronchoalveolar lavage. Am J Pathol 1979;97:149–206.
  5. Karol MH, Hauth BA, Alarie Y: Pulmonary hypersensitivity to hexyl isocyanate-ovalbumin aerosol in guinea pigs. Toxicol Appl Pharmacol 1979;51:73–80.
  6. Yoshizawa Y, Ohtsuka M, Noguchi K, Uchida Y, Suko M, Hasegawa S: Hypersensitivity pneumonitis induced by toluene diisocyanate: Sequelae of continuous exposure [see comments]. Ann Intern Med 1989;110:31–34.
  7. Baur X: Hypersensitivity pneumonitis (extrinsic allergic alveolitis) induced by isocyanates. J Allergy Clin Immunol 1995;95:1004–1010.
  8. Grammer LC, Harris KE, Malo JL, Cartier A, Patterson R: The use of an immunoassay index for antibodies against isocyanate human protein conjugates and application to human isocyanate disease. J Allergy Clin Immunol 1990;86:94–98.
  9. Baur X: Immunologic cross-reactivity between different albumin-bound isocyanates. J Allergy Clin Immunol 1983;71:197–205.
  10. Schuyler M, Gott K, Fei R, Edwards B: Experimental hypersensitivity pneumonitis: Location of transferring cells. Lung 1998;176:213–225.
  11. Schuyler M, Gott K, Shopp G, Crooks L: CD3+ and CD4+ cells adoptively transfer experimental hypersensitivity pneumonitis. Am Rev Respir Dis 1992Dec;146:1582–1588.
  12. Gudmundsson G, Bosch A, Davidson BL, Berg DJ, Hunninghake GW: Interleukin-10 modulates the severity of hypersensitivity pneumonitis in mice. Am J Respir Cell Mol Biol 1998;19:812–818.

Article / Publication Details

First-Page Preview
Abstract of Clinical Investigations

Received: February 10, 2003
Accepted: November 26, 2012
Published online: August 18, 2003
Issue release date: May – June

Number of Print Pages: 8
Number of Figures: 4
Number of Tables: 2

ISSN: 0025-7931 (Print)
eISSN: 1423-0356 (Online)

For additional information: https://www.karger.com/RES


Copyright / Drug Dosage / Disclaimer

Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.